Publications by authors named "Violaine Scarfogliere"
Background: In chronic intermittent hemodialysis, heparin is the standard anticoagulant as is the use of acid-containing dialysate. Regional anticoagulation (RA) with a calcium-free, citrate-containing dialysate has been developed. We compared RA using a calcium-free, citrate-free dialysate, routinely used in our center, versus systemic heparinization.
View Article and Find Full Text PDFHemodialysis (HD) patients are at risk for severe COVID-19 and cannot comply with social distancing. SARS-COV2 seroprevalence in French patients and caregivers after the first wave of COVID-19 is unknown. SeroCOVIDial is a prospective study conducted between June and December 2020.
View Article and Find Full Text PDFBackground: Daily management to shield chronic dialysis patients from SARS-CoV-2 contamination makes patient care cumbersome. There are no screening methods to date and a molecular biology platform is essential to perform RT-PCR for SARS-CoV-2; however, accessibility remains poor. Our goal was to assess whether the tools routinely used to monitor our hemodialysis patients could represent reliable and quickly accessible diagnostic indicators to improve the management of our hemodialysis patients in this pandemic environment.
View Article and Find Full Text PDFArticle Synopsis
- COVID-19 poses significant risks for patients with end-stage renal disease (ESRD), with a study showing 5.5% of 2336 dialysis patients diagnosed with the virus.
- Among those followed for over 28 days, 37% experienced severe outcomes and 28% died, with oxygen therapy and decreased lymphocyte counts identified as major risk factors.
- The study noted that chronic use of angiotensin II receptor blockers (ARBs) may protect against mortality, while treatments like azithromycin and hydroxychloroquine showed no benefit for patients with COVID-19.